Mira Pharmaceuticals (FRA:K6S) Interest Expense: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:K6S Mira Pharmaceuticals Inc FRA:K6S
13 GF Score
Price €0.80
! 1 Warning Sign
View Full Analysis

What is Mira Pharmaceuticals Interest Expense?

Mira Pharmaceuticals FRA:K6S +0.56% 13 Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:K6S with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mira Pharmaceuticals's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mira Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was € -0.95 Mil. Mira Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. Mira Pharmaceuticals has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Mira Pharmaceuticals  (FRA:K6S) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mira Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-0.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

Mira Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Mira Pharmaceuticals had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Mira Pharmaceuticals Inc has no debt.

Mira Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for Mira Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mira Pharmaceuticals Interest Expense Chart

Mira Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.02 -0.01 -3.17 0.00 0.00

Mira Pharmaceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:K6S
13GF Score
Mira Pharmaceuticals Inc FRA:K6S
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mira Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €0.00 Mil mean?
Mira Pharmaceuticals (FRA:K6S) has a Interest Expense of €0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Mira Pharmaceuticals and its competitors.
Is Mira Pharmaceuticals' Interest Expense too high?
Mira Pharmaceuticals' current Interest Expense is €0.00 Mil. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' Interest Expense compare to NSRX and SCLX?
Mira Pharmaceuticals' Interest Expense of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Mira Pharmaceuticals and its competitors. Mira Pharmaceuticals's current Interest Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (FRA:K6S) has a current Interest Expense of €0.00 Mil. The current Interest Expense is €0.00 Mil. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Mira Pharmaceuticals (FRA:K6S), the current Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mira Pharmaceuticals Business Description

Other Exchanges MIRA:USA
Address 1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score

Get the complete analysis for FRA:K6S

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price